
    
      This multicenter, uncontrolled, open label treatment study is to assess the safety of CGMS in
      guiding insulin pump therapy for 24 weeks by measuring mild, moderate, and severe
      hypoglycemic episodes in patients with type 1 and type 2 diabetes and gastroparesis.
    
  